Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.

Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA.

J Clin Oncol. 2008 Aug 20;26(24):4047-8. doi: 10.1200/JCO.2008.18.3525. No abstract available.

PMID:
18711201
2.

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK.

Br J Dermatol. 2009 Nov;161(5):1045-51. doi: 10.1111/j.1365-2133.2009.09290.x.

PMID:
19558553
3.

Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.

Ahn HK, Lee S, Sun JM, Lee J, Park SH, Park JO, Park YS, Kang WK, Lim HY.

Invest New Drugs. 2012 Aug;30(4):1768-72. doi: 10.1007/s10637-011-9707-4. No abstract available.

PMID:
21720741
4.

Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.

Daimon M, Kato T, Kaino W, Takase K, Karasawa S, Wada K, Kameda W, Susa S, Oizumi T, Tomita Y, Kato T.

Jpn J Clin Oncol. 2012 Aug;42(8):742-7. doi: 10.1093/jjco/hys076.

5.

A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.

Berchem G, Dewilde S, Mahassen P.

Bull Soc Sci Med Grand Duche Luxemb. 2009;(1):7-9.

PMID:
19514172
6.

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.

Lacouture ME, Reilly LM, Gerami P, Guitart J.

Ann Oncol. 2008 Nov;19(11):1955-61. doi: 10.1093/annonc/mdn389.

7.

[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].

Bolenz C, Trojan L, Honeck P, Schöppler G, Herrmann E, Alken P, Michel MS, Häcker A.

Aktuelle Urol. 2009 Jan;40(1):31-6. doi: 10.1055/s-2008-1038176. German.

PMID:
19177319
8.

Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.

Bukowski RM.

Clin Genitourin Cancer. 2009 Jan;7(1):9-10. doi: 10.3816/CGC.2009.n.001. No abstract available.

PMID:
19213661
9.

Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma.

Lamarca A, Feliu J, Barriuso J.

Br J Cancer. 2012 Mar 13;106(6):1246. doi: 10.1038/bjc.2012.25. No abstract available.

10.

[New drugs; sunitinib and sorafenib].

van Bronswijk H, Dubois EA, Osanto S, Cohen AF.

Ned Tijdschr Geneeskd. 2007 Dec 29;151(52):2888-90. Dutch.

PMID:
18257434
11.

[Role of VEGFR-TKIs in the treatment of renal cell carcinoma].

Kondo T.

Nihon Jinzo Gakkai Shi. 2012;54(5):574-80. Review. Japanese. No abstract available.

PMID:
22991835
12.

Reversible cardiomyopathy associated with sunitinib and sorafenib.

Uraizee I, Cheng S, Moslehi J.

N Engl J Med. 2011 Oct 27;365(17):1649-50. doi: 10.1056/NEJMc1108849. No abstract available.

13.

Kidney cancer: Does hypothyroidism predict clinical outcome?

Rini B.

Nat Rev Urol. 2011 Jan;8(1):10-1. doi: 10.1038/nrurol.2010.191. No abstract available.

PMID:
21116300
14.

Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.

Loriot Y, Boudou-Rouquette P, Billemont B, Ropert S, Goldwasser F.

Ann Oncol. 2008 Nov;19(11):1975. doi: 10.1093/annonc/mdn566. No abstract available.

15.

A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD.

J Natl Cancer Inst. 2008 Feb 20;100(4):282-4. doi: 10.1093/jnci/djm311. No abstract available.

16.

Two new drugs for renal cell carcinoma.

[No authors listed]

Med Lett Drugs Ther. 2007 Feb 26;49(1255):18-20. No abstract available.

PMID:
17325624
17.

[Cutaneous side effects of sorafenib and sunitinib].

Autier J, Mateus C, Wechsler J, Spatz A, Robert C.

Ann Dermatol Venereol. 2008 Feb;135(2):148-53; quiz 147, 154. doi: 10.1016/j.annder.2007.12.006. Review. French. No abstract available.

PMID:
18342102
18.

Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?

Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G.

Thyroid. 2009 May;19(5):539-40. doi: 10.1089/thy.2008.0367. No abstract available.

PMID:
19416001
19.

[Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].

Pérez López G, Carrasco De La Fuente M, Menacho Román M, González Albarrán O, Cano Megías M.

Endocrinol Nutr. 2011 Feb;58(2):94-6. doi: 10.1016/j.endonu.2010.09.012. Spanish. No abstract available.

PMID:
21333617
20.

Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.

Di Fiore F, Rigal O, Ménager C, Michel P, Pfister C.

Br J Cancer. 2011 Dec 6;105(12):1811-3. doi: 10.1038/bjc.2011.507.

Items per page

Supplemental Content

Support Center